natgillin/translations-raw huggingface dataset:
A stable aqueous formulation consisting essentially of bG-CSF- T133pAF-20K PEG, a citrate buffer wherein the citrate buffer has a molarity of about 30mM, arginine wherein arginine has a molarity of about 250mM, and optionally a counter ion for arginine. 
Stabilna vodena formulacija, naznačena time što se uglavnom sastoji od bG-CSF-T133pAF-20K PEG, citratnog pufera, gdje citratni pufer ima molarnost od otprilike 30mM, arginina, gdje arginin ima molarnost od otprilike 250 mM i, izborno, protuiona za arginin.
wherein: the mixture is heat-treated prior, during or after packaging, or ii) the mixture is made of one or more heat-treated ingredients. 
Cc) = pakiranje smjese, gdje se: i) - smjesu toplinski obradi prije, tijekom ili nakon pakiranja, ili ii) = smjesu načini od jednog ili više toplinski obrađenih sastojaka.
The genetically modified mouse of item 9, wherein the target cell is a tumor cell, and the immunoadhesin or antibody specifically binds an epitope of the tumor cell. 
(b) ciljana stanica je tumorska stanica, a imunoadhezin ili antitijelo se specifično vezuje za epitop tumorske stanice.
a mechanical filter device adapted for separating the processed feed mixture into a higher viscosity fraction and a lower viscosity fraction, and allowing the lower viscosity fraction to pass through the filter device; 
– uređaj za mehaničko filtriranje s rasponom filtarskih otvora između 1 µm i 500 µm, prilagođen za odvajanje frakcije više viskoznosti od obrađene dovodne smjese i dopuštanje da frakcija niže viskoznosti prođe kroz uređaj za filtriranje;
The compound according to claim 15, wherein the compound is 2-(2- ethylbenzyl)-4,5-dihydroxylsophthalonitrile. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je spoj 2-(2-etilbenzil)-4,5-dihidroksiizoftalonitril.
The management system as claimed in claim 1, wherein said data and said additional data is transferred to a computing means capable of storing measurements made by said at least one sensor. 
Sustav upravljanja prema zahtjevu 1, naznačen time da se navedeni podaci i navedeni dodatni podaci prenose na računalna sredstva sposobna za pohranu mjerenja koja provodi najmanje jedan navedeni senzor (24).
A C2-8 dialkylamino may be represented by the following groups: 
C2.g dialkilamino može biti predstavljen slijedećim grupama:
Diethylaminoethyl (DEAE) or diethyl-(2-hydroxy-propyl)aminoethyl (QAE) have chloride as counter ion, for instance. 
Dietilaminoetil (DEAEF) ili dietil(2-hidroksi-propiljaminoetil (QAF) posjeduje na primjer klorid kao ion suprotnog naboja,.
In most embodiments of the invention, the fuel/aerosol generating means combination will be attached to a mouthend piece, such as a foil lined paper or cellulose acetate/plastic tubes illustrated in the figures, although a mouthend piece may be provided separately, e.g., in the form of a cigarette holder. 
U mnogim realizacijama izuma, kombinacija gorivo/sredstvo za generiranje aerosola bit će spojena za dio usnog kraja, kao što je papir obložen folijom ili cijev od acetata celuloze/plastike kao što je ilustrirano na slikama, mada dio usnog kraja može biti osiguran odvojeno, n.pr., u obliku držača za cigarete.
In certain cases, a human antibody may be at least 60%, 70%, 80%, 90%, or at least 95%, or even at least 96%, 97%, 98%, or 99% identical in amino acid sequence to the amino acid sequence encoded by the germline immunoglobulin gene. 
Izolirano monoklonalno protutijelo ili njegov fragment koji se veže na antigen, prema bilo kojem od prethodnih zahtjeva, naznačen/o time, da obuhvaća jaki lanac koji ima najmanje 95%, 96%, 97%, 98% ili 99% identiteta sekvence prema SEQ ID NO:9; i slabi lanac koji ima najmanje 95%, 96%, 97%, 98% ili 99% identiteta sekvence prema SEQ ID NO:10.
the leucine at position 8 of the FG loop (SEQ ID NO: 75) is substituted with an amino acid selected from the group consisting of A, C, E, F, H, I, K, M, N, Q, R, S, T, V, W, or Y; 
(viii) leucin na položaju 8 u petlji FG (SEQ ID NO: 75) je zamijenjen aminokiselinom koju se bira iz skupine koju čine A, C, E, F, H, I, K, M, N, Q, R, S, T, V, W te Y;
The composition for the use according to claim 7, consisting of alpha-tocopheryl acetate and hydrogenated polydecene. 
Pripravak za uporabu u skladu s patentnim zahtjevom 7, koji se sastoji od alfa-tokoferil acetata i hidrogeniranog polidecena.
vinyl aromatic polymers and/or vinyl aromatic copolymers in an amount equal to at least 50% by weight, 
vinilaromatske polimere i/ili vinilaromatske kopolimere u količini koja iznosi najmanje 50%, težinski,
Calculation of the percentage coverage of the fetal genome 
Datum podnošenja europske prijave patenta:
a circuit board including a module circuit electrically coupled to said light emitting diode, said circuit board at least partially contained within the cavity of said housing, said module circuit having a thermistor to sense heat from said light emitting diode. 
- < tiskanu pločicu sa sklopom modula 1 električno priključena na navedenu LED diodu, navedena tiskana pločica barem je djelomično smještena u šupljinu navedenog kućišta, navedeni sklop modula uključuje termistor kojim odčitava toplinu iz navedene LED diode.
In yet another aspect the present invention relates to the use of the mucosal bioadhesive slow release carrier according to the invention for the manufacture of a medicament to treat herpes simplex virus 1 (HSV-1), herpes simplex virus 2 (HSV-2) Epstein-Barr virus, human papilloma virus, cytomegalovirus, variacella-Zoster virus, Kaposi's sarcoma due to human herpes V8 and genital warts due to human papilloma virus. 
Primjena nosača bioadhezivnog za mukozu sa sporim oslobađanjem prema patentnom zahtjevu 19, naznačen time što se za proizvodnju lijeka za liječenje herpes simpleks kompleksa 1 (HSV-1), genitalnog herpesa (HSV-2), infekcije varičela zoster virusom (VZV), Epstein-Barr virusom, humanim herpes virusom 8, ptičje gripe, zaušnjaka, HIV-a, infekcije respiratornim sincicijalnim virusom, gripe, parainfluence i infekcije citomegalovirusom.
The present invention also provides a rotigotine drug substance comprising at least about 5%, preferably at least about 10%, of the novel polymorphic form of rotigotine as defined above. 
Rotigotin ljekovita supstanca koja sadrži najmanje 5% polimorfnog oblika Rotigotina kako je definirano u bilo kojem od patentnih zahtjeva 1-2.
Additionally, the product can, if desired, be further purified by various well known techniques, such as recrystallization, reprecipitation or the various chromatography techniques, notably column chromatography or preparative thin layer chromatography. 
Uz to, produkt se može, po želji, daljnje pročistiti različitim dobro poznatim tehnikama, poput prekristalizacije, pretaloženja ili različitih tehnika kromatografije, osobito kromatografijom na stupcu ili preparativnom tankoslojnom kromatografijom.
The present invention also provides an antibody molecule according to the present invention for use in the treatment or prophylaxis of pain, particularly pain associated with inflammation. The present invention further provides the use of an antibody molecule, fragment or composition according to the present invention in the manufacture of a medicament for the treatment or prophylaxis of a pathological disorder that is mediated by OX40 or associated with an increased level of OX40, in particular the pathological disorder is rheumatoid arthritis, asthma or COPD. 
Protutijelo ili farmaceutski pripravak za uporabu prema zahtjevu 24, ili uporaba prema zahtjevu 25, naznačena time što je patološki poremećaj psorijaza. Protutijelo ili farmaceutski pripravak za uporabu prema zahtjevu 24, ili uporaba prema zahtjevu 25, naznačena time što je patološki poremećaj sistemski eritemski lupus. Fuzijski protein naznačen time što sadrži protutijelo prema bilo kojem od zahtjeva 1 do 4 ili 6 koje veže OX40 i dva protutijela jedne domene vezana na protutijelo koje veže OX40.
discharging of the emulsion of fluid components from the washing chamber through the outlet of the washing and separating container, and facilitating the location of the solid component next to the outlet and discharging the solid component from the outlet, 
- < razmještanja spremnika (1) za ispiranje i odvajanje na takav način da je čvrsta komponenta pored odvoda - pražnjenja čvrste komponente iz spremnika za ispiranje i odvajanje iz odvoda (103).
Panel according to Claim 1, characterized in that the first detent means of the lower detent engagement point (14) has a detent projection (15), and in that the second detent means of the lower detent engagement point (14) has a detent depression (16) adapted to said detent projection. 
Panel u skladu s patentnim zahtjevom 1, naznačen time što prvi zaponski element na donjem mjestu međudjelovanja zapona (14) ima zaponsko izbočenje (15), te što drugi zaponski element na donjem mjestu međudjelovanja zapona (14) ima zaponsko udubljenje (16) prilagođen za navedeno zaponsko izbočenje.
The use of aspect 14 or 15, wherein the patient is selected from a Type 1-diabetic patient, a Type 2-diabetic patient, in particular a diet-treated Type 2-diabetic patient, a sulfonylurea-treated Type 2-diabetic patient, a far-advanced stage Type 2-diabetic patient and/or a long-term insulin-treated Type 2-diabetic patient. 
Uporaba prema zahtjevu 13 ili 14, naznačena time što je pacijent odabran od pacijenta s dijabetesom tipa 1, pacijenta s dijabetesom tipa 2, posebno s dijabetesom tipa 2 liječenog ishranom, pacijenta s dijabetesom tipa 2 liječenog sulfonilureom, pacijenta s dijabetesom tip 2 u daleko uznapredovalom stadiju i/ili pacijenta s dijabetesom tip 2 dugotrajno liječenog inzulinom.
The solid cosmetic product according to claim 1, wherein the inner non-effervescent material is present in an amount of 2 to 40 wt % based on the solid cosmetic product. 
Kruti kozmetički proizvod prema bilo kojem od prethodnih zahtjeva naznačen time da je unutarnji ne-pjenušavi materijal prisutan u količini od 2 do 40 masenih % u odnosu na kruti kozmetički proizvod, a vanjski pjenušavi materijal je prisutan u količini od 60 do 98 masenih % u odnosu na kruti kozmetički proizvod.
Combination according to claim 2 or 3, characterized in that the compound of formula (I) is (1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol of formula (I'), or an acid addition salt thereof, whereby the acid addition salt of hydrochloride is preferred. 
Kombinacija prema zahtjevu 2 ili 3, naznačena time da je spoj sa formulom (1) (1R,2R)-3-(3-Dimetilamino-1-etil- 2-metil-propil)-fenol sa formulom (T'), ili njihova kisela adicijska sol, pri čemu je poželjna hidrokloridna adicijska sol.
iv) reacting the obtained 17a-cyanomethyl-17B-hydroxy-estr-5(10)-ene-3-one of formula (II) with 1-1.5 equivalent of pyridinium tribromide in pyridine solution at a temperature between 0 and 60°C, then purifying the obtained crude dienogest of formula (I) by recrystallization and preparative HPLC. 
HR P20100102 TI iv) reakciju dobivenog 17a-cijanometil-17B-hidroksi-estr-5(10)-en-3-ona formule (II) sa 1-1.5 ekvivalenta piridinij tribromida u otopini piridina pri temperaturi između 0 i 60%C, zatim pročišćavanje dobivenog sirovog dienogesta formule (IT) rekristalizacijom i preparativnom HPLC.
to have an increased Fc receptor binding affinity as compared to the non-glycoengineered antibody; and 
(iti) kako bi imalo povećani afinitet vezanja Fc receptora u usporedbi prema protutijelu koje nije bilo podvrgnuto glikoinženjeringu; i
angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof, 
(1i) - antagonist receptora angiotenzina II ili njegova farmaceutski prihvatljiva sol,
L is selected from 
L se bira između
Furthermore, the container 3 is provided with a pressure medium feed opening 21 that can be closed off by a spring-loaded ball valve or by a membrane that can be penetrated. 
Nadalje, spremnik 3 sadrži i otvor za napajanje medijem pod tlakom 21, koji se može zatvoriti pomoću kuglastog ventila na oprugu, ili pomoću membrane koja se može penetrirati.
a serum albumin binding immunoglobulin single variable domain, and 
jednostruka varijabilna domena imunoglobulina koja se veže na serum-albumin, i
A mould according to claim 14 or 15, at least an area, and preferably the entire area, of said first surface (110) having said indentations (9). 
Kalup sukladno Zahtjevu 12 1 13, barem područje, po mogućnosti čitavo područje, navedene prve površine (110) ima navedene udubine (9).
separating of the solid phase with the vitamin D tracer compound and bound monoclonal antibody from the binding buffer, and optionally washing of the solid phase; and 
(f) izdvajanja čvrste faze koja nosi spoj za vizualizaciju vitamina D i vezano monoklonsko protutijelo iz pufera za vezanje i izbornog ispiranja čvrste faze; i
Recently, further selective agonists of S1P have also been described in the patent literature (WO 04 058149, WO 04 024673, WO 03 061567). 
Nedavno su u patentnoj literaturi (WO 04 058149, WO 04 024673, WO 03 061567) također opisani daljnji selektivni agonisti SIP.
The tire vulcanizer according to one of claim 1 and claim 2, wherein the platen includes a plate connecting section in which the mutually adjacent divided platens of the plurality of divided platens are connected to each other and positioned via a plate-shaped member. 
dio za spajanje ploča u kojem su susjedni odijeljeni diskovi od većeg odijeljenih diskova međusobno spojeni i pričvršćeni s pomoću pločastog elementa.
Other means of enhancing permeation of buprenorphine, such as the use of iontophoretic means, are also contemplated to be within the scope of the present invention. 
Namjera je da i ostali načini poboljšavanja prodiranja buprenorfina, kao što je korištenje iontoforetskih sredstava, također budu unutar opsega ovoga izuma.
A method for providing at least a part of a building, comprising the steps of: 
PATENTNI ZAHTJEVI Postupak pribavljanja barem dijela zgrade, sadrži korake:
phenylC1-6alkyl, said phenylC1-6alkyl being unsubstituted or substituted with one, two or three halogen; 
fenilC1−6alkil, pri čemu je navedeni fenilC1−6alkil nesupstituiran ili supstituiran s jednim, dva ili tri halogena; ili
An antibody of any one of claims 1-7, a conjugate of claim 8 or a pharmaceutical composition of claim 9 for use in a method of treating or preventing a cancer disease or disorder involving a cell expressing CLDN6 and being characterized by association of CLDN6 with its cell surface in a subject. 
Antitijelo prema bilo kojem od patentnih zahtjeva 1-6, konjugat prema patentnom zahtjevu 7 ili farmaceutska kompozicija prema patentnom zahtjevu 8 za upotrebu u postupku za liječenje ili prevenciju bolesti raka ili poremećaja koji obuhvaća stanicu koja eksprimira CLDNG6 i koja je naznačena vezom CLDNG6 s njezinom staničnom površinom kod subjekta.
The crude compound was purified on a normal phase analytical column to yield 605 ug of compound (the product was an isomeric mixture) 7,9-acrolein acetal-10-a-acetyl-2′-R,S-hydroxy-3′-S-isobutyl-3′-N-t-butoxy carbonyl taxane of Formulas 31 and 33, which may be separated by liquid chromatography. 
Sirovi spoj je bio očišćen na normalnoj fazi analitičkog stupca, da bi se dobilo 605 ug spoja (produkt je bio izomerna smjesa) 7,9-akrolein acetal-10-a-acetal-2'-R,S-hidroksi-3'-S-izobutil-3'-N-t-butoksi karbonil taksana iz formula 31 133, koje mogu biti odvojene tekućinskom kromatografijom
The ability of various rapamycin carbohydrate derivatives to release free rapamycin via hydrolysis in whole blood was investigated by spiking the compounds in human whole blood and then measuring by HPLC the amount of free rapamycin in the samples at 1 hour to determine the extent of hydrolysis. 
Sposobnost različitih ugljikohidratnih derivata rapamicina da otpuštaju slobodni rapamicin putem hidrolize u punoj krvi istražena je sondiranjem spojeva u punoj ljudskoj krvi i mjerenjem količine slobodnog rapamicina pomoću HPLC u uzorcima nakon 1 sat kako bi se odredio stupanj hidrolize.
In addition to the so-called pure or monocomponent microcrystalline cellulose varieties mixtures of various types of microcrystalline cellulose formed with colloidal silicon dioxide can also be used, which contain about 98% by weight of microcrystalline cellulose and about 2% by weight of colloidal silicon dioxide. 
Uz tzv. čistu ili jednokomponentnu mikrokristalnu celulozu mogu se koristiti različite smjese različitih tipova mikrokristalne celuloze s koloidnim silicijevim dioksidom, koji sadrži oko 98% (težinski) mikrokristalne celuloze i oko 2% (težinski) koloidnog silicijevog dioksida.
The antibody as claimed in any one of claims 1 to 5 which inhibits the alternative complement pathway with an IC50 of 20-200 pM as measured by in vitro hemolytic assay when using human C5 depleted serum that is reconstituted with 100 pM human C5. 
Protutijelo prema bilo kojem od zahtjeva 1 do 5, naznačeno time, da posjeduje alternativni komplementni put s ICsg od 20-200 pM, kao što se mjeri pomoću hemolitičkog testiranja in vitro, uporabom iscrpljenog seruma humanog C5, koji se rekonstituira s 100 pM humanog C5.
The nano-fibrillar cellulose gel according to claim 15, characterized in that the efficiency of the nano-fibrillar cellulose gel with respect to the total energy consumption in order to achieve a certain Brookfield viscosity is higher than the efficiency of a corresponding nano-fibrillar cellulose gel having been fibrillated in the absence of fillers and/or pigments or a corresponding gel not containing filler and/or pigment. 
Gel od nanofibrilarne celuloze u skladu s patentnim zahtjevom 15, HR P20171818 T1 naznačen time što viskoznost gela od nanofibrilarne celuloze prema Brookfieldu je manja od viskoznosti odgovarajuće suspenzije nanofibrilarne celuloze prema Brookfieldu jer je fibrilirana u odsutnosti punila i/ili pigmenata.
Process of claim 4, wherein the carrier has a BET surface area, measured according to ISO 5794-1, of at least 10 m2/g. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što nosač ima BET vanjske površine, što je izmjereno u skladu s ISO 5794-1, od najmanje 10 m"/g.
The method according to claim 21, wherein the ink or coating composition is selected from the group of inks consisting of screen-printing inks, gravure inks, and flexographic inks. 
Postupak sukladno jednom od patentnih zahtjeva 7 do 12, naznačen time, da je tinta ili smjesa za premazivanje odabrana iz skupine koju čine tinte za tiskanje zaslonom, tinte za graviranje i fleksografske tinte.
The compound according to claim 1, wherein R1 is methyl. The compound according to claim 1, wherein R2 is selected from 
Spoj opisan u točki 1 patentnog zahtjeva ili farmaceutski prihvatljiva sol istoga, pri čemu je R1 metil.
A compound according to formula (I) wherein n is 0 or 1; 
Spoj prema formuli (I) pri čemu n je 0 ili 1;
a concentration of lidocaine between 0.75 and 1.25%; and 
- < koncentraciju lidokaina ili njegove soli, kao lokalni anestetik, između 0,75 1 1,25%; 1
The system (10) according to claim 1, characterized in that the system (10) further comprises: a chest board (16); and a height adjustable handrail (17) to help a patient maintain a steady position. 
Sustav (10) prema zahtjevu 1, naznačen time da sustav (10) dalje obuhvaća: prsnu ploču (16); i rukohvat s podešavanjem visine (17) za pomoć pacijentu da održi stabilan položaj.
An expression vector containing at least one nucleic acid sequence according to claim 6. 
Ekspresijski vektor naznačen time da sadrži barem jednu sekvencu nukleinske kiseline prema zahtjevu 3.
a fluorescent protein, GFP, 
(c) fluorescentnog proteina;
A method according to any one of claims 1 to 9 wherein CRC is a Metastatic CRC. 
Kombinacija za uporabu prema bilo kojem od zahtjeva 1 do 5 naznačena time da rak debelog crijeva je metastatski rak debelog crijeva (MCRC).
Composition for use according to claim 9, wherein said composition comprises adult stem cells obtained at a concentration equal to 150x103 cells/ml and is administered once a week intravenously. 
Pripravak za uporabu prema patentnom zahijevu 9, pri čemu spomenuti pripravak sadrži odrasle matične stanice dobivene u koncentraciji jednakoj 150x10* stanica/ mL te se administrira intravenozno jednom tjedno.
For the avoidance of doubt, the formula depicted above and the term (3R)-1-phenethyl-3-(9H-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane is meant to embrace the salts in dissociated, partially dissociated or undissociated form, for example in aqueous solution. 
Kako bi se izbjegle nedoumice, gore navedene formule i termin (3R)-1-fenetil-3-(9H-ksanten-9-karboniloks1)-1- azoniabiciklo[2.2.2]oktan obuhvaća soli u disociranom, djelomično disociranom ili nedisociranom obliku, na primjer u vodenoj otopini.
The compound according to claim 13 or 14 or a pharmacologically acceptable salt thereof, wherein R6 is a hydrogen atom. 
Spoj u skladu sa patentnim zahtjevom 13, 14 ili 15 ili njegova farmakološki prihvatljiva sol, gdje R6 ili R8 predstavlja atom vodika.
The system of claim 19, wherein the liquid fraction from the second high temperature high pressure separator is fed to the mass transfer unit. 
Sustav u skladu s patentnim zahtjevom 29, naznačen time, da se tekuća frakcija iz separatora (40) visoke temperature / visokog pritiska dovodi u jedinicu za atmosfersko frakcioniranje (54).
The pharmaceutical composition of any one of embodiments 46 to 49, wherein said buffer is selected from the group consisting of succinate, citrate, and phosphate buffers. 
Farmaceutski sastav prema bilo kojem zahtjevu od 26 do 29, naznačen time da je navedeni pufer odabran iz grupe koja se sastoji od sukcinatnih, citratnih, i fosfatnih pufera.
The composition of claim 12, wherein the ligand is a polymeric material that binds to prion proteins. 
Postupak ili pripravak sukladno bilo kojem od zahtjeva 1 do 4, pri čemu je ligand polimerni materijal koji se veže za protein priona.
inserting a genomic fragment into an endogenous rodent CD47 locus in a rodent embryonic stem cell, said genomic fragment comprising exons 2-7 of a human CD47 gene, thereby forming the humanized CD47 gene at the endogenous rodent CD47 locus; 
(a) umetanju genomskog fragmenta u lokus endogenog glodavčkog CD47 u glodavačkoj embrionskoj matičnoj stanici, gdje navedeni genomski fragment sadrži egzone 2-7 iz ljudskog gena CD47, čime se dobije humanizirani gen CD47 na lokusu endogenog glodavčkog CD47;
The composition of any one of statements 1 to 20 further comprising a pharmaceutically acceptable carrier. 
Spoj sukladno bilo kojem od zahtjeva 1 do 7 nadalje sadrži farmaceutski prihvatljiv nosač.
The antibody-drug conjugate according to claim 1, wherein the linker and the antitumor compound is represented by the following formula: -(Succinimid-3-yl -N)—CH2CH2CH2CH2CH2—C(═O)-GGFG-NH—CH2CH2—O—CH2—C(═O)—(NH-DX). 
(NH-DX) predstavlja grupu predstavljenu pomoću formule koja slijedi: gdje dušikov atom iz amino grupe na poziciji 1 je pozicija vezivanja, i
The method of clause 21 comprising combining the composition after step (2) with a pharmaceutically acceptable carrier. 
Postupak prema zahtjevu 13 ili 14, naznačen time, da obuhvaća sjedinjavanje sastava s farmaceutski prihvatljivim nosačem nakon koraka (2).
An orally administrable chewable composition in unit dosage form comprising a set oil-in-water emulsion in which the aqueous phase is gelled and in which the oil phase comprises a fish oil, wherein the weight of said unit dose is 0.25-3g. 
PATENTNI ZAHTJEVI wanman ao Oralno primjenjiv pripravak za žvakanje u obliku jedinične doze koji sadrži ulje-u-vodi emulziju gdje je vodena faza gelirana 1 gdje uljna faza obuhvaća riblje ulje, pri čemu je težina te jedinične doze 0.25-3g.